A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies

Ilda Hoxhaj, Laurenz Govaerts, Steven Simoens, Walter Van Dyck, Isabelle Huys, Iñaki Gutiérrez-Ibarluzea and Stefania Boccia
Additional contact information
Ilda Hoxhaj: Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Roma, Italy
Laurenz Govaerts: Healthcare Management Centre, Vlerick Business School, 9000 Ghent, Belgium
Steven Simoens: Department of Pharmaceutical and Pharmacological Sciences, Catholic University of Leuven-KU Leuven, 3000 Leuven, Belgium
Walter Van Dyck: Healthcare Management Centre, Vlerick Business School, 9000 Ghent, Belgium
Isabelle Huys: Department of Pharmaceutical and Pharmacological Sciences, Catholic University of Leuven-KU Leuven, 3000 Leuven, Belgium
Iñaki Gutiérrez-Ibarluzea: Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, 48902 Basque, Spain
Stefania Boccia: Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Roma, Italy

IJERPH, 2020, vol. 17, issue 21, 1-21

Abstract: Background: Omics technologies, enabling the measurements of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics), are valuable tools for personalized decision-making. We aimed to identify the existing value assessment frameworks used by health technology assessment (HTA) doers for the evaluation of omics technologies through a systematic review. Methods: PubMed, Scopus, Embase and Web of Science databases were searched to retrieve potential eligible articles published until 31 May 2020 in English. Additionally, through a desk research in HTA agencies’ repositories, we retrieved the published reports on the practical use of these frameworks. Results: Twenty-three articles were included in the systematic review. Twenty-two frameworks, which addressed genetic and/or genomic technologies, were described. Most of them derived from the ACCE framework and evaluated the domains of analytical validity, clinical validity and clinical utility. We retrieved forty-five reports, which mainly addressed the commercial transcriptomic prognostics and next generation sequencing, and evaluated clinical effectiveness, economic aspects, and description and technical characteristics. Conclusions: A value assessment framework for the HTA evaluation of omics technologies is not standardized and accepted, yet. Our work reports that the most evaluated domains are analytical validity, clinical validity and clinical utility and economic aspects.

Keywords: value assessment frameworks; omics technologies; omics sciences; personalized medicine; health technology assessment; genomics; proteomics; metabolomics; transcriptomics (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/21/8001/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/21/8001/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:21:p:8001-:d:437656

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().